Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428351 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4ELTA4HSIGMAR1TOP2A | |
| SCHEMBL3423092 | 0.79 | LTA4H (0.47) | ALDH1A1KDM4ELTA4HTOP2ALMNA | |
| SCHEMBL23901605 | 0.78 | ALDH1A1 (0.54) | ALDH1A1SIGMAR1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL15251849 | 0.78 | CTSK (0.49) | — | |
| SCHEMBL27869981 | 0.78 | CTSK (0.49) | — | |
| SCHEMBL2479744 | 0.76 | OPRK1 (0.55) | LTA4HSIGMAR1SMN1; SMN2PPIDPOLB | |
| SCHEMBL23910329 | 0.76 | MMP9 (0.50) | — | |
| SCHEMBL10472517 | 0.76 | TDP1 (0.51) | ALDH1A1LTA4HLMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL9625673 | 0.76 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL11796548 | 0.75 | SIGMAR1 (0.57) | ALDH1A1LTA4HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527090-B | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2023-05-26 | — | — | CN | disclosed |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| CN-111527090-A | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | 拜耳公司 | 2020-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | ALDH1A1 1120/4885KDM4E 3924/4885LTA4H 783/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | ALDH1A1 1149/4885KDM4E 3993/4885LTA4H 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.